AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10194706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic MRI using a half-Fourier RARE sequence (imaging time 2 seconds)
Number of subjects: 32
Study 10194706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic MRI
Number of subjects: 32
Study 10194706 — intervention group
Group type: COMPARATOR
Intervention: Cystourethrography
Number of subjects: 32
Study 10194706 — intervention group
Group type: COMPARATOR
Intervention: Colpocystorectography
Number of subjects: 32
Study 7786960 — intervention group
Group type: EXPERIMENTAL
Intervention: L-365,260, 30 mg qid
Number of subjects: 88
Study 7786960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 2394020 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of intra-epithelial haemorrhage shortly after myringotomy with grommet insertion
Number of subjects: 92
Study 2394020 — intervention group
Group type: EXPERIMENTAL
Intervention: Grommet in situ on follow-up 6 months later
Number of subjects: 92
Study 2394020 — intervention group
Group type: COMPARATOR
Intervention: Absence of haemorrhage and grommet extrusion
Number of subjects: 92
Study 375401 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (2 mg)
Number of subjects: 60
Study 375401 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (4 mg)
Number of subjects: 60
Study 375401 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (60 mg)
Number of subjects: 60
Study 31680065 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygieno-dietetic recommendations
Number of subjects: 0
Study 31680065 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0
Study 31680065 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29134997 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoexcitation and subsequent electronic energy relaxation and redistribution at low temperature (10 K) and room temperature (300 K)
Number of subjects: 8
Study 29134997 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐radiative relaxation involving non‐adiabatic transitions
Number of subjects: 8
Study 29134997 — intervention group
Group type: EXPERIMENTAL
Intervention: Excited state dynamics on a picosecond time‐scale
Number of subjects: 8
Study 29134997 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-ring energy transfer
Number of subjects: 8
Study 27884857 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 hour online tutorial and a 3.5 hour skills building workshop in interprofessional shared decision-making (SDM)
Number of subjects: 0
Study 24359265 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ablative 1550 nm erbium-glass FPS
Number of subjects: 100
Study 24359265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative 10,600 nm CO2 FS
Number of subjects: 100
Study 24359265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (FPS and CO2 FS)
Number of subjects: 100
Study 24359265 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment within 3 years of scar development
Number of subjects: 100
Study 24359265 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment >3 years after scar development
Number of subjects: 100
Study 22357722 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted sleep (4 h/night)
Number of subjects: 30
Study 22357722 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (9 h/night)
Number of subjects: 30
Study 19789403 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawthorn 450 mg twice daily
Number of subjects: 120
Study 19789403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 17514695 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair
Number of subjects: 1656
Study 17514695 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1656
Study 15140343 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg daily
Number of subjects: 1456
Study 15140343 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 1456
Study 15140343 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 50 mg once a week
Number of subjects: 1456
Study 11453887 — intervention group
Group type: COMPARATOR
Intervention: Perindopril (4, 8, 16 mg) in HV; 4 mg in CHF patients
Number of subjects: 16
Study 9743163 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 336 microg/d (4 puffs bid)
Number of subjects: 339
Study 9743163 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) 800 microg/d (4 puffs bid)
Number of subjects: 339
Study 9743163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 9743163 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 339
Study 9743163 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 339
Study 9743163 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups (BDP, TA, and placebo)
Number of subjects: 339
Study 7532931 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative resection (group 1)
Number of subjects: 49
Study 7532931 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative resection (group 2)
Number of subjects: 49
Study 7532931 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not undergo surgery (group 2)
Number of subjects: 49
Study 3208513 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 10 mg x 2 for seven days
Number of subjects: 153
Study 3208513 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 25 mg x 2 for seven days
Number of subjects: 153
Study 3208513 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 50 mg x 2 for seven days
Number of subjects: 153
Study 29925684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal carbetocin
Number of subjects: 37
Study 29925684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 26837629 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet diary modality
Number of subjects: 67
Study 26837629 — intervention group
Group type: COMPARATOR
Intervention: Voice diary modality
Number of subjects: 67
Study 26837629 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diary participation
Number of subjects: 67
Study 23755123 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 977
Study 23755123 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 977
Study 22533544 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of cART
Number of subjects: 112
Study 22533544 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 weeks of cART
Number of subjects: 112
Study 22533544 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 112
Study 20880120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m² on days 1, 4, 8, and 11 of a 3-week cycle with rituximab 375 mg/m² on day 1 (21 patients)
Number of subjects: 42
Study 20880120 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib 1.6 mg/m² and rituximab on days 1, 8, 15, and 22 of a 5-week cycle (with rituximab given only in cycles 1 and 4) (21 patients)
Number of subjects: 42
Study 18397330 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole for 5 days, 20 mg/kg/day for children and 1.5 g/day for adults
Number of subjects: 112
Study 18397330 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of ornidazole, 30 mg/kg for children and 2 g for adults
Number of subjects: 112
Study 15898859 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with recent onset of BC (63 women)
Number of subjects: 12177
Study 15898859 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with longer established onset of BC (181 women)
Number of subjects: 12177
Study 15898859 — intervention group
Group type: COMPARATOR
Intervention: Women with no BC (11,933 women)
Number of subjects: 12177
Study 12075271 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 0
Study 12075271 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 0
Study 10568908 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid application as the study intervention in three trials.
Number of subjects: 30
Study 10568908 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent steroid use allowed in seven trials.
Number of subjects: 30
Study 10568908 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-randomization steroid use instructions specified in 3 of 14 trials where steroids were not part of the intervention.
Number of subjects: 30
Study 10568908 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid dosing during the intervention reported as a secondary outcome measure in four trials.
Number of subjects: 30
Study 10568908 — intervention group
Group type: EXPERIMENTAL
Intervention: Free concurrent steroid use during the intervention allowed in 11 RCTs.
Number of subjects: 30
Study 8733656 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03%
Number of subjects: 401
Study 8733656 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl alcohol alone (control)
Number of subjects: 401
Study 8253823 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient perturbations
Number of subjects: 12
Study 8253823 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous perturbations
Number of subjects: 12
Study 8253823 — intervention group
Group type: COMPARATOR
Intervention: Vision deprivation (eyes-open vs blindfolded)
Number of subjects: 12
Study 3023712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporine, 14 mg/kg/d
Number of subjects: 21
Study 3023712 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 21
Study 3023712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine after switch from vehicle
Number of subjects: 21
Study 3023712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine therapy
Number of subjects: 21
Study 29451145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 114
Study 29451145 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 114
Study 27062947 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina combined with core stability exercises
Number of subjects: 88
Study 27062947 — intervention group
Group type: COMPARATOR
Intervention: Tuina alone
Number of subjects: 88
Study 26168950 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented premolded earplugs
Number of subjects: 0
Study 26168950 — intervention group
Group type: COMPARATOR
Intervention: Standard earplugs (inexpensive, frequently distributed for free at music events)
Number of subjects: 0
Study 22810757 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC+B12 (pegylated interferon α plus ribavirin plus vitamin B12)
Number of subjects: 94
Study 22810757 — intervention group
Group type: COMPARATOR
Intervention: SOC (pegylated interferon α plus ribavirin)
Number of subjects: 94
Study 21947489 — intervention group
Group type: EXPERIMENTAL
Intervention: Honan intraocular pressure reducer (HIPR)
Number of subjects: 60
Study 21947489 — intervention group
Group type: COMPARATOR
Intervention: non-Honan intraocular pressure reducer (non-HIPR)
Number of subjects: 60
Study 19583558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment close to the menopausal transition
Number of subjects: 0
Study 19583558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 0
Study 16874014 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBAT protocol (daily celecoxib, 13-cisretinoic acid, metronomic temozolomide, low-dose etoposide)
Number of subjects: 22
Study 16874014 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBAT protocol
Number of subjects: 22
Study 12642757 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-intervention (Group A)
Number of subjects: 164
Study 12642757 — intervention group
Group type: EXPERIMENTAL
Intervention: Work site visit (Group B)
Number of subjects: 164
Study 12642757 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Group C)
Number of subjects: 164
Study 10840169 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of exogenous testosterone
Number of subjects: 0
Study 10840169 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 7636778 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone
Number of subjects: 20
Study 7636778 — intervention group
Group type: EXPERIMENTAL
Intervention: mental arithmetic stress
Number of subjects: 20
Study 7636778 — intervention group
Group type: COMPARATOR
Intervention: video-watching control task
Number of subjects: 20
Study 2166452 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM)
Number of subjects: 187
Study 2166452 — intervention group
Group type: COMPARATOR
Intervention: im opioids
Number of subjects: 187
Study 2166452 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (EM) with positive HSV serology
Number of subjects: 187
Study 2166452 — intervention group
Group type: COMPARATOR
Intervention: im opioids with positive HSV serology
Number of subjects: 187
Study 7265455 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (drug group)
Number of subjects: 100
Study 7265455 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 100
Study 31683146 — intervention group
Group type: EXPERIMENTAL
Intervention: Grow When Required Neural Networks (GWRNNs) with dynamic adjustment of activated input connections
Number of subjects: 0
Study 31683146 — intervention group
Group type: EXPERIMENTAL
Intervention: GWRNNs with added localisation information to the input data stream
Number of subjects: 0
Study 30853212 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 98
Study 30853212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 98
Study 30853212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 27836533 — intervention group
Group type: COMPARATOR
Intervention: Phone reminder
Number of subjects: 749
Study 27836533 — intervention group
Group type: COMPARATOR
Intervention: Text reminder
Number of subjects: 749
Study 25345798 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion therapy
Number of subjects: 196
Study 25345798 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 196
Study 23806847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocyte donors (treated)
Number of subjects: 18
Study 23806847 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle (control)
Number of subjects: 18
Study 21741606 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 196
Study 21741606 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training (RT)
Number of subjects: 196
Study 21741606 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (AT/RT)
Number of subjects: 196
Study 19875410 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone initiated <7 days after AMI
Number of subjects: 6632
Study 19875410 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone initiated >=7 days after AMI
Number of subjects: 6632
Study 16721750 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation ON, patient aware
Number of subjects: 10
Study 16721750 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation ON, patient blind
Number of subjects: 10
Study 16721750 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation OFF, patient aware
Number of subjects: 10
Study 16721750 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation OFF, patient blind
Number of subjects: 10
Study 16721750 — intervention group
Group type: COMPARATOR
Intervention: Stimulation ON vs OFF
Number of subjects: 10
Study 16721750 — intervention group
Group type: COMPARATOR
Intervention: Interaction of awareness and stimulation condition
Number of subjects: 10
Study 14660506 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HCHO) at 8.5 g CHO x kg(‐1) x day(‐1)
Number of subjects: 7
Study 14660506 — intervention group
Group type: COMPARATOR
Intervention: Control diet (Con) at 5.4 g CHO x kg(‐1) x day(‐1)
Number of subjects: 7
Study 14660506 — intervention group
Group type: COMPARATOR
Intervention: Control diet (Con)
Number of subjects: 7
Study 11763248 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 0
Study 11763248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9407678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus epidural morphine (3 mg every 8 hours)
Number of subjects: 60
Study 9407678 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA) with morphine (2 mg bolus, 0.15 mg/h)
Number of subjects: 60
Study 8143997 — intervention group
Group type: EXPERIMENTAL
Intervention: rectal cisapride (30 mg three times daily)
Number of subjects: 23
Study 8143997 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 8143997 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine (1 mg/kg over 3 hours)
Number of subjects: 23
Study 3341154 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid treatment
Number of subjects: 53
Study 3341154 — intervention group
Group type: COMPARATOR
Intervention: Surgical removal of nasal polyps
Number of subjects: 53
Study 31474354 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib plus bevacizumab
Number of subjects: 97
Study 31474354 — intervention group
Group type: COMPARATOR
Intervention: Single-agent niraparib
Number of subjects: 97
Study 28418399 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 59
Study 28418399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 26163202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobeglitazone (0.5 mg) administered with amlodipine (10 mg)
Number of subjects: 24
Study 26163202 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg) administered with lobeglitazone (0.5 mg)
Number of subjects: 24
Study 24294746 — intervention group
Group type: EXPERIMENTAL
Intervention: M+M+G (Metronidazole + Metronidazole + Lactobacillus casei var rhamnosus - Lcr 35)
Number of subjects: 60
Study 24294746 — intervention group
Group type: COMPARATOR
Intervention: M+M (Metronidazole + Metronidazole)
Number of subjects: 60
Study 21944122 — intervention group
Group type: EXPERIMENTAL
Intervention: Eraser laser prostate enucleation
Number of subjects: 60
Study 21944122 — intervention group
Group type: COMPARATOR
Intervention: bipolar transurethral prostate resection
Number of subjects: 60
Study 19072600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog-appeasing pheromone (DAP)
Number of subjects: 45
Study 19072600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 16567885 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music (Group 2)
Number of subjects: 78
Study 16567885 — intervention group
Group type: COMPARATOR
Intervention: Not listening to music (Group 1)
Number of subjects: 78
Study 16567885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 12679426 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate
Number of subjects: 61
Study 12679426 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg testosterone enanthate
Number of subjects: 61
Study 12679426 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg testosterone enanthate
Number of subjects: 61
Study 12679426 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg testosterone enanthate
Number of subjects: 61
Study 12679426 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg testosterone enanthate
Number of subjects: 61
Study 10783538 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection procedures with negative outcome feedback
Number of subjects: 201
Study 10783538 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative outcome feedback from a racially similar experimenter
Number of subjects: 201
Study 10783538 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative outcome feedback from a racially different experimenter
Number of subjects: 201
Study 8923550 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving bar stimulus with manipulated retinal-image parameters (2-D stretch/shrinkage, 2-D rotation, 2-D translation)
Number of subjects: 0
Study 1557933 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 100
Study 3888464 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine
Number of subjects: 14
Study 3888464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30086140 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtitles displayed concurrently with the speech
Number of subjects: 0
Study 30086140 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtitles displayed after speech offset
Number of subjects: 0
Study 30086140 — intervention group
Group type: COMPARATOR
Intervention: No subtitles displayed
Number of subjects: 0
Study 26706665 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 333
Study 26706665 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (personalized, telephone-based program targeting 7% weight loss)
Number of subjects: 333
Study 26706665 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention and Metformin
Number of subjects: 333
Study 26706665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 24886455 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical traction (12 treatments over six consecutive weeks)
Number of subjects: 0
Study 24886455 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 22243632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated fat (HSF) diet
Number of subjects: 88
Study 22243632 — intervention group
Group type: EXPERIMENTAL
Intervention: High-saturated fat (HSF-DHA) diet
Number of subjects: 88
Study 19582583 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous nouns (multiple meanings)
Number of subjects: 0